AGAP2 is a multifunctional GTPase-activating protein with dual roles in cell survival and cancer progression. As a GAP for ARF1 and ARF5, AGAP2 isoform 1 prevents neuronal apoptosis by enhancing PI3 kinase activity through coupling with metabotropic glutamate receptor signaling and Homer scaffolding proteins, while also mediating NGF anti-apoptotic effects via nuclear PI3 kinase activation 1. Isoform 2 protects cells from apoptosis through Akt stimulation and regulates AP-1-dependent endosomal trafficking 1. Critically, AGAP2 is overexpressed in multiple cancer types and promotes cancer cell invasion and apoptosis prevention 1. The associated lncRNA AGAP2-AS1 is aberrantly elevated across numerous malignancies including glioma, colorectal, lung, ovarian, and breast cancers 2. AGAP2-AS1 functions as a potent oncogene promoting cancer cell proliferation, migration, and invasion 2. Meta-analysis of 948 patients demonstrated that AGAP2-AS1 overexpression predicts reduced overall survival (HR=1.77) and disease-free survival, with association to lymph node metastasis, advanced TNM stage, and larger tumor size 3. Mechanistically, AGAP2-AS1 acts as a ceRNA, sponging miR-193a-3p in laryngeal carcinoma and interacting with BRD7 to promote c-Myc expression in melanoma 45. These findings position AGAP2/AGAP2-AS1 as promising prognostic biomarkers and therapeutic targets for cancer management.